Pelthos Therapeutics, Inc. (PTHS)
9.48
+0.18
(+1.94%)
USD |
NYAM |
Nov 06, 10:23
Pelthos Therapeutics Enterprise Value : 83.13M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 83.13M |
| November 04, 2026 | 86.29M |
| November 03, 2026 | 88.64M |
| November 02, 2026 | 91.39M |
| October 30, 2026 | 83.50M |
| October 29, 2026 | 110.05M |
| October 28, 2026 | 107.08M |
| October 27, 2026 | 102.47M |
| October 26, 2026 | 105.07M |
| October 23, 2026 | 111.77M |
| October 22, 2026 | 121.40M |
| October 21, 2026 | 118.09M |
| October 20, 2026 | 124.78M |
| October 19, 2026 | 123.89M |
| October 16, 2026 | 123.48M |
| October 15, 2026 | 123.89M |
| October 14, 2026 | 123.85M |
| October 13, 2026 | 124.00M |
| October 12, 2026 | 121.14M |
| October 09, 2026 | 124.78M |
| October 08, 2026 | 124.78M |
| October 07, 2026 | 126.60M |
| October 06, 2026 | 128.42M |
| October 05, 2026 | 124.78M |
| October 02, 2026 | 125.15M |
| Date | Value |
|---|---|
| October 01, 2026 | 124.22M |
| September 30, 2026 | 126.68M |
| September 29, 2026 | 126.34M |
| September 28, 2026 | 127.57M |
| September 25, 2026 | 131.06M |
| September 24, 2026 | 131.85M |
| September 23, 2026 | 136.01M |
| September 22, 2026 | 134.97M |
| September 21, 2026 | 134.63M |
| September 18, 2026 | 132.78M |
| September 17, 2026 | 131.77M |
| September 16, 2026 | 120.76M |
| September 15, 2026 | 124.11M |
| September 14, 2026 | 130.14M |
| September 11, 2026 | 129.99M |
| September 10, 2026 | 131.96M |
| September 09, 2026 | 135.64M |
| September 08, 2026 | 139.84M |
| September 04, 2026 | 139.10M |
| September 03, 2026 | 139.13M |
| September 02, 2026 | 141.63M |
| September 01, 2026 | 140.84M |
| August 31, 2026 | 138.09M |
| August 28, 2026 | 140.51M |
| August 27, 2026 | 141.51M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Travere Therapeutics, Inc. | 4.820B |
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.42M |
| Revenue (Quarterly) | 15.60M |
| Total Expenses (Quarterly) | 39.02M |
| EPS Diluted (Quarterly) | -6.616 |
| Gross Profit Margin (Quarterly) | 68.40% |
| Profit Margin (Quarterly) | -150.1% |
| Earnings Yield | -278.0% |
| Normalized Earnings Yield | -213.10 |